ORAMED PHARMACEUTICALS INC (ORMP) Fundamental Analysis & Valuation

NASDAQ:ORMP • US68403P2039

3.4 USD
+0.07 (+2.1%)
Last: Mar 11, 2026, 08:18 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This ORMP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

Taking everything into account, ORMP scores 5 out of 10 in our fundamental rating. ORMP was compared to 193 industry peers in the Pharmaceuticals industry. ORMP has a great financial health rating, but its profitability evaluates not so good. ORMP is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

3

1. ORMP Profitability Analysis

1.1 Basic Checks

  • In the past year ORMP was profitable.
  • ORMP had a negative operating cash flow in the past year.
  • ORMP had negative earnings in 4 of the past 5 years.
  • In the past 5 years ORMP always reported negative operating cash flow.
ORMP Yearly Net Income VS EBIT VS OCF VS FCFORMP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

  • With an excellent Return On Assets value of 19.89%, ORMP belongs to the best of the industry, outperforming 97.93% of the companies in the same industry.
  • ORMP's Return On Equity of 21.57% is amongst the best of the industry. ORMP outperforms 91.71% of its industry peers.
Industry RankSector Rank
ROA 19.89%
ROE 21.57%
ROIC N/A
ROA(3y)-10.8%
ROA(5y)-15.12%
ROE(3y)-11.25%
ROE(5y)-17.59%
ROIC(3y)N/A
ROIC(5y)N/A
ORMP Yearly ROA, ROE, ROICORMP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

  • The Profit Margin of ORMP (2192.60%) is better than 99.48% of its industry peers.
  • ORMP does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 2192.6%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ORMP Yearly Profit, Operating, Gross MarginsORMP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. ORMP Health Analysis

2.1 Basic Checks

  • ORMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ORMP has been reduced compared to 1 year ago.
  • ORMP has more shares outstanding than it did 5 years ago.
  • ORMP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ORMP Yearly Shares OutstandingORMP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ORMP Yearly Total Debt VS Total AssetsORMP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • An Altman-Z score of 4.46 indicates that ORMP is not in any danger for bankruptcy at the moment.
  • ORMP's Altman-Z score of 4.46 is fine compared to the rest of the industry. ORMP outperforms 74.09% of its industry peers.
  • There is no outstanding debt for ORMP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.46
ROIC/WACCN/A
WACC8.83%
ORMP Yearly LT Debt VS Equity VS FCFORMP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

  • ORMP has a Current Ratio of 22.24. This indicates that ORMP is financially healthy and has no problem in meeting its short term obligations.
  • ORMP has a better Current ratio (22.24) than 92.23% of its industry peers.
  • ORMP has a Quick Ratio of 22.24. This indicates that ORMP is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of ORMP (22.24) is better than 92.23% of its industry peers.
Industry RankSector Rank
Current Ratio 22.24
Quick Ratio 22.24
ORMP Yearly Current Assets VS Current LiabilitesORMP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ORMP Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 726.67% over the past year.
  • Looking at the last year, ORMP shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)726.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%333.33%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • ORMP is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -30.19% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y825.33%
EPS Next 2Y-167.21%
EPS Next 3Y-66.87%
EPS Next 5Y-30.19%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ORMP Yearly Revenue VS EstimatesORMP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2025 500K 1M 1.5M 2M 2.5M
ORMP Yearly EPS VS EstimatesORMP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1 -1

More info and screens

Find the best growth stocksShow best growing peers

4

4. ORMP Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 2.74, the valuation of ORMP can be described as very cheap.
  • Compared to the rest of the industry, the Price/Earnings ratio of ORMP indicates a rather cheap valuation: ORMP is cheaper than 97.93% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.15. ORMP is valued rather cheaply when compared to this.
  • ORMP is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 2.74
Fwd PE N/A
ORMP Price Earnings VS Forward Price EarningsORMP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ORMP Per share dataORMP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

  • ORMP's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • ORMP's earnings are expected to decrease with -66.87% in the coming years. This may justify a cheaper valuation.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y-167.21%
EPS Next 3Y-66.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. ORMP Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 7.61%, ORMP is a good candidate for dividend investing.
  • ORMP's Dividend Yield is rather good when compared to the industry average which is at 0.71. ORMP pays more dividend than 98.45% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, ORMP pays a better dividend.
Industry RankSector Rank
Dividend Yield 7.61%

5.2 History

  • ORMP is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
ORMP Yearly Dividends per shareORMP Yearly Dividends per shareYearly Dividends per share 2026 0.05 0.1 0.15 0.2

5.3 Sustainability

DPN/A
EPS Next 2Y-167.21%
EPS Next 3Y-66.87%
ORMP Yearly Income VS Free CF VS DividendORMP Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

More info and screens

Find the best dividend stocksShow peers with best dividend

ORMP Fundamentals: All Metrics, Ratios and Statistics

ORAMED PHARMACEUTICALS INC

NASDAQ:ORMP (3/11/2026, 8:18:13 PM)

3.4

+0.07 (+2.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-08
Earnings (Next)03-25
Inst Owners27.78%
Inst Owner Change49.57%
Ins Owners15.95%
Ins Owner Change15.95%
Market Cap135.32M
Revenue(TTM)2.00M
Net Income(TTM)43.85M
Analysts43.33
Price TargetN/A
Short Float %1.67%
Short Ratio2.37
Dividend
Industry RankSector Rank
Dividend Yield 7.61%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date01-16
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1852.45%
Min EPS beat(2)859.8%
Max EPS beat(2)2845.1%
EPS beat(4)3
Avg EPS beat(4)510.54%
Min EPS beat(4)-1762.75%
Max EPS beat(4)2845.1%
EPS beat(8)6
Avg EPS beat(8)-569.36%
EPS beat(12)10
Avg EPS beat(12)-366.78%
EPS beat(16)11
Avg EPS beat(16)-276.91%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-0.78%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 2.74
Fwd PE N/A
P/S 67.66
P/FCF N/A
P/OCF N/A
P/B 0.67
P/tB 0.67
EV/EBITDA N/A
EPS(TTM)1.24
EY36.47%
EPS(NY)-1.29
Fwd EYN/A
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS0.05
BVpS5.11
TBVpS5.11
PEG (NY)0
PEG (5Y)N/A
Graham Number11.94
Profitability
Industry RankSector Rank
ROA 19.89%
ROE 21.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 2192.6%
GM N/A
FCFM N/A
ROA(3y)-10.8%
ROA(5y)-15.12%
ROE(3y)-11.25%
ROE(5y)-17.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.75%
Cap/Sales 0.9%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.24
Quick Ratio 22.24
Altman-Z 4.46
F-Score5
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)324.08%
Cap/Depr(5y)449.45%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)726.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%333.33%
EPS Next Y825.33%
EPS Next 2Y-167.21%
EPS Next 3Y-66.87%
EPS Next 5Y-30.19%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y39.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.49%
OCF growth 3YN/A
OCF growth 5YN/A

ORAMED PHARMACEUTICALS INC / ORMP FAQ

What is the fundamental rating for ORMP stock?

ChartMill assigns a fundamental rating of 5 / 10 to ORMP.


What is the valuation status for ORMP stock?

ChartMill assigns a valuation rating of 4 / 10 to ORAMED PHARMACEUTICALS INC (ORMP). This can be considered as Fairly Valued.


How profitable is ORAMED PHARMACEUTICALS INC (ORMP) stock?

ORAMED PHARMACEUTICALS INC (ORMP) has a profitability rating of 3 / 10.


What are the PE and PB ratios of ORAMED PHARMACEUTICALS INC (ORMP) stock?

The Price/Earnings (PE) ratio for ORAMED PHARMACEUTICALS INC (ORMP) is 2.74 and the Price/Book (PB) ratio is 0.67.


How financially healthy is ORAMED PHARMACEUTICALS INC?

The financial health rating of ORAMED PHARMACEUTICALS INC (ORMP) is 9 / 10.